$IRWD
IRONWOOD PHARMACEUTICALS INC

2023 Q3 Form 10-Q Financial Statement

#000155837023014242 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $113.7M $107.4M
YoY Change 4.7% 10.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $36.05M $52.48M
YoY Change 25.95% 74.23%
% of Gross Profit
Research & Development $32.99M $34.58M
YoY Change 185.71% 201.93%
% of Gross Profit
Depreciation & Amortization $507.0K $270.0K
YoY Change 39.67% -25.0%
% of Gross Profit
Operating Expenses $69.03M $87.06M
YoY Change 71.87% 109.4%
Operating Profit $40.02M -$1.083B
YoY Change -41.55% -2046.17%
Interest Expense $9.839M $1.840M
YoY Change 545.6% -16.63%
% of Operating Profit 24.58%
Other Income/Expense, Net -$8.091M $6.917M
YoY Change -664.23% -469.89%
Pretax Income $31.93M -$1.076B
YoY Change -54.32% -2100.97%
Income Tax $18.00M $13.30M
% Of Pretax Income 56.37%
Net Earnings $15.32M -$1.062B
YoY Change -69.55% -2964.58%
Net Earnings / Revenue 13.47% -989.17%
Basic Earnings Per Share $0.10 -$6.84
Diluted Earnings Per Share $0.09 -$6.84
COMMON SHARES
Basic Shares Outstanding 156.0M 155.3M
Diluted Shares Outstanding 186.9M 155.4M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.2M $175.3M
YoY Change -80.81% -65.24%
Cash & Equivalents $110.2M $175.3M
Short-Term Investments
Other Short-Term Assets $18.90M $23.29M
YoY Change 128.79% 109.73%
Inventory
Prepaid Expenses
Receivables $124.5M $119.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $253.6M $317.6M
YoY Change -63.72% -48.59%
LONG-TERM ASSETS
Property, Plant & Equipment $5.630M $5.876M
YoY Change -15.47% -15.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.823M $3.920M
YoY Change 342.99% 349.54%
Total Long-Term Assets $270.5M $285.6M
YoY Change -20.77% -20.19%
TOTAL ASSETS
Total Short-Term Assets $253.6M $317.6M
Total Long-Term Assets $270.5M $285.6M
Total Assets $524.1M $603.2M
YoY Change -49.63% -38.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.698M $3.505M
YoY Change 490.94% 1005.68%
Accrued Expenses $75.29M $96.16M
YoY Change 186.03% 321.2%
Deferred Revenue $2.600M $1.500M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $199.3M $199.1M
YoY Change
Total Short-Term Liabilities $280.6M $305.4M
YoY Change 934.7% 1210.8%
LONG-TERM LIABILITIES
Long-Term Debt $523.1M $598.0M
YoY Change 32.16% 51.21%
Other Long-Term Liabilities $30.95M $31.04M
YoY Change 235.41% 378.12%
Total Long-Term Liabilities $30.95M $31.04M
YoY Change 235.41% 378.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $280.6M $305.4M
Total Long-Term Liabilities $30.95M $31.04M
Total Liabilities $311.5M $336.4M
YoY Change 757.16% 1029.36%
SHAREHOLDERS EQUITY
Retained Earnings -$1.698B -$1.713B
YoY Change 127.78% 115.3%
Common Stock $1.375B $1.367B
YoY Change 2.9% 2.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$323.2M -$345.7M
YoY Change
Total Liabilities & Shareholders Equity $524.1M $603.2M
YoY Change -49.63% -38.18%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $15.32M -$1.062B
YoY Change -69.55% -2964.58%
Depreciation, Depletion And Amortization $507.0K $270.0K
YoY Change 39.67% -25.0%
Cash From Operating Activities $32.46M $34.96M
YoY Change -53.02% -43.02%
INVESTING ACTIVITIES
Capital Expenditures $22.63M $999.5M
YoY Change -34380.3% -1135886.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$22.63M -$999.5M
YoY Change 34180.3% 1135686.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -74.99M 399.1M
YoY Change -9508.78% -365.55%
NET CHANGE
Cash From Operating Activities 32.46M 34.96M
Cash From Investing Activities -22.63M -999.5M
Cash From Financing Activities -74.99M 399.1M
Net Change In Cash -65.15M -565.5M
YoY Change -193.31% 535.3%
FREE CASH FLOW
Cash From Operating Activities $32.46M $34.96M
Capital Expenditures $22.63M $999.5M
Free Cash Flow $9.834M -$964.5M
YoY Change -85.78% -1669.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.ironwoodpharma.com/20230630#CollaborativeArrangementsMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.ironwoodpharma.com/20230630#CollaborativeArrangementsMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.ironwoodpharma.com/20230630#CollaborativeArrangementsMember
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001446847
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.ironwoodpharma.com/20230630#CollaborativeArrangementsMember
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#HedgingLiabilitiesCurrent
CY2022Q4 us-gaap Derivative Liability Valuation Technique Extensible List
DerivativeLiabilityValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#GainLossOnDerivativeInstrumentsNetPretax
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34620
dei Entity Registrant Name
EntityRegistrantName
IRONWOOD PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3404176
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Summer Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
621-7722
dei Security12b Title
Security12bTitle
Class A common stock, $0.001 par value
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
dei Trading Symbol
TradingSymbol
IRWD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
156029186
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175321000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
656203000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
118990000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115458000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22500000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7715000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
788000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1250000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
317599000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
780626000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
510000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
485000
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
14589000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5876000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6288000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13319000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14023000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4096000
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
257900000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
283661000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3920000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
847000
CY2023Q2 us-gaap Assets
Assets
603220000
CY2022Q4 us-gaap Assets
Assets
1100519000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3505000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
483000
CY2023Q2 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
20122000
CY2022Q4 irwd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5258000
CY2023Q2 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
79585000
CY2022Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16700000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3095000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3065000
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
199083000
CY2022Q4 us-gaap Hedging Liabilities Current
HedgingLiabilitiesCurrent
19000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
305390000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25525000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15598000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16599000
CY2023Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
197974000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
396251000
CY2023Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
400000000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31035000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9766000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
156027648
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156027648
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154026949
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154026949
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
156000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
154000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1366989000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1348600000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1712849000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-696376000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-345704000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
652378000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
53785000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1010361000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
-1073000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-346777000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
652378000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
603220000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1100519000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107382000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97231000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
211443000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
194760000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107382000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97231000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
211443000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
194760000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34577000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11452000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47424000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22274000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52484000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30124000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83601000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58985000
CY2023Q2 irwd Restructuring Expense Benefit
RestructuringExpenseBenefit
13011000
irwd Restructuring Expense Benefit
RestructuringExpenseBenefit
13011000
CY2023Q2 irwd Asset Acquisition Acquired In Process Research And Development Expense
AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense
1090449000
irwd Asset Acquisition Acquired In Process Research And Development Expense
AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense
1090449000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
1190521000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
41576000
us-gaap Costs And Expenses
CostsAndExpenses
1234485000
us-gaap Costs And Expenses
CostsAndExpenses
81259000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1083139000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
55655000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1023042000
us-gaap Operating Income Loss
OperatingIncomeLoss
113501000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1840000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2207000
us-gaap Interest Expense
InterestExpense
3367000
us-gaap Interest Expense
InterestExpense
4548000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
8757000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1018000
us-gaap Investment Income Net
InvestmentIncomeNet
16029000
us-gaap Investment Income Net
InvestmentIncomeNet
1248000
CY2022Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-681000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
19000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
49000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6917000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1870000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12681000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3251000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1076222000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
110250000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13256000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16705000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33403000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34369000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1089478000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1089478000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
37080000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
37080000
us-gaap Profit Loss
ProfitLoss
-1043764000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1043764000
us-gaap Profit Loss
ProfitLoss
75881000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
75881000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27291000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-27291000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27291000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-27291000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1062187000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1062187000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
37080000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37080000
us-gaap Net Income Loss
NetIncomeLoss
-1016473000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1016473000
us-gaap Net Income Loss
NetIncomeLoss
75881000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
75881000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.84
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155367000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153304000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154912000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155550000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155367000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
184876000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154912000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187315000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
652378000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1629000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7131000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
45714000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
706852000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1366000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8265000
CY2023Q2 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
26218000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1089478000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-346777000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
605911000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1521000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6089000
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
90489000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
38801000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
517783000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4315000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6601000
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
32896000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
37080000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
532883000
us-gaap Profit Loss
ProfitLoss
-1043764000
us-gaap Profit Loss
ProfitLoss
75881000
us-gaap Depreciation
Depreciation
556000
us-gaap Depreciation
Depreciation
715000
us-gaap Share Based Compensation
ShareBasedCompensation
15395000
us-gaap Share Based Compensation
ShareBasedCompensation
12690000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-19000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1164000
irwd Fair Value Adjustment Of Convertible Note Hedging Instrument
FairValueAdjustmentOfConvertibleNoteHedgingInstrument
1115000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
887000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1053000
irwd Asset Acquisition Acquired In Process Research And Development Expense
AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense
1090449000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
27060000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
29594000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11057000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-21394000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1264000
irwd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-704000
irwd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-650000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
270000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-128000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18333000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10765000
irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-2083000
irwd Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
-9558000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-970000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-978000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
4067000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5998000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115134000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
125489000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97000
irwd Payments To Acquire Productive Assets Net Of Cash Acquired
PaymentsToAcquireProductiveAssetsNetOfCashAcquired
999492000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-999505000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5347000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5937000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
120699000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
400000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2295000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
126394000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
403052000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-241156000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-481319000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-115764000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
657938000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
621864000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176619000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
506100000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175321000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
504365000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1298000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1735000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176619000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
506100000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists (“GC-C agonists”) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”) and for pediatric patients ages 6-17 years-old suffering from functional constipation (“FC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”), Mexico and Saudi Arabia, to adult men and women suffering from IBS-C or chronic constipation in Japan, IBS-C in China, and pediatric patients ages 6-17 years old with FC in the U.S. Linaclotide is available under the trademarked name CONSTELLA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration for North America with <span style="color:#212529;background:#ffffff;">AbbVie</span>, total net sales of LINZESS in the U.S., as recorded by <span style="color:#212529;background:#ffffff;">AbbVie</span>, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and <span style="color:#212529;background:#ffffff;">AbbVie</span>. Additionally, development costs are shared equally between the Company and AbbVie. The Company and AbbVie are exploring ways to enhance the clinical profile of LINZESS by studying linaclotide in additional indications, populations and formulations to assess its potential to treat various conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside of the U.S., the Company earns royalties as a percentage of net sales of products containing linaclotide as an active ingredient by the Company’s collaboration partners. AbbVie has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “<span style="color:#212529;background:#ffffff;">AbbVie</span> License Territory”). In addition, <span style="color:#212529;background:#ffffff;">AbbVie</span> has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS. Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop, manufacture, and commercialize linaclotide in Japan. AstraZeneca AB (together with its affiliates) (“AstraZeneca”), the Company’s partner in China, has the exclusive right to develop, manufacture, and commercialize products containing linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a collaboration and license option agreement (the “COUR Collaboration Agreement”) with COUR Pharmaceutical Development Company, Inc. (“COUR”), a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The COUR Collaboration Agreement grants the Company an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for primary biliary cholangitis, a rare autoimmune disease targeting the liver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 4, Collaboration, License, and Other Agreements, to these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is also advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome (“IC/BPS”) and endometriosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In June 2023, the Company completed a tender offer to purchase outstanding ordinary shares of VectivBio Holding AG (“VectivBio”), a clinical-stage biotechnology company focused on the discovery and development of treatments for severe, rare GI conditions for which there is a significant unmet medical need. As of June 30, 2023, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Ironwood holds 98% of VectivBio’s outstanding ordinary shares and intends to effect a statutory squeeze-out merger under Swiss law to acquire all remaining shares.Through the acquisition, the Company is advancing apraglutide, a next-generation, synthetic peptide analog of glucagon-like peptide-2 (“GLP-2”), for rare GI diseases, including short bowel syndrome with intestinal failure (“SBS-IF”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the condensed consolidated financial statements include those related to fair value of assets acquired and liabilities assumed in acquisitions; revenue recognition; accounts receivable; useful lives of long-lived assets, impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">liabilities; fair value of derivatives; income taxes, including uncertain tax positions and the valuation allowance for deferred tax assets; research and development expenses; contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Certain prior period amounts have been reclassified to conform to current period presentation.</p>
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1089478000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
37080000
us-gaap Profit Loss
ProfitLoss
-1043764000
us-gaap Profit Loss
ProfitLoss
75881000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27291000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-27291000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1062187000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
37080000
us-gaap Net Income Loss
NetIncomeLoss
-1016473000
us-gaap Net Income Loss
NetIncomeLoss
75881000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1062187000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
38192000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1016473000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
78103000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1300000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
627000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
627000
us-gaap Operating Lease Cost
OperatingLeaseCost
1254000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155367000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153304000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154912000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155550000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155367000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
184876000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154912000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187315000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.84
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8298000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13979000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11106000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15081000
CY2023Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
119000000.0
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
130000000.0
CY2023Q2 irwd Accounts Receivable Net Of Accounts Payable Current And Noncurrent
AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent
103000000.0
CY2022Q4 irwd Accounts Receivable Net Of Accounts Payable Current And Noncurrent
AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent
104400000
CY2022Q2 irwd Threshold Percentage Of Collateralized Value
ThresholdPercentageOfCollateralizedValue
1.02
CY2022Q2 irwd Threshold Percentage Of Collateralized Value
ThresholdPercentageOfCollateralizedValue
1.02
CY2023Q2 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
79585000
CY2022Q4 irwd Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16700000
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
10500000
CY2023Q2 irwd Employee Related Liabilities Current Tax Withholding Share Based Payment Arrangement
EmployeeRelatedLiabilitiesCurrentTaxWithholdingShareBasedPaymentArrangement
6500000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13100000
CY2023Q2 irwd Other Accrued Liabilities Current Uninvoiced Vendor Liabilities
OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities
11100000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1500000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3800000
CY2022Q4 irwd Other Accrued Liabilities Current Uninvoiced Vendor Liabilities
OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities
3600000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
19000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
31988000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12268000
CY2023Q2 irwd Accrued Transaction Costs Current
AccruedTransactionCostsCurrent
18596000
CY2023Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
9228000
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6646000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
656000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13127000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3776000
us-gaap Operating Lease Cost
OperatingLeaseCost
1256000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
269000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
264000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
540000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
523000
CY2023Q2 us-gaap Lease Cost
LeaseCost
896000
CY2022Q2 us-gaap Lease Cost
LeaseCost
891000
us-gaap Lease Cost
LeaseCost
1794000
us-gaap Lease Cost
LeaseCost
1779000
us-gaap Operating Lease Payments
OperatingLeasePayments
1520000
us-gaap Operating Lease Payments
OperatingLeasePayments
1583000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1545000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3126000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3189000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3252000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3317000
CY2023Q2 irwd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
8285000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22714000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4021000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
18693000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3095000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15598000
CY2015Q2 us-gaap Payments For Hedge Investing Activities
PaymentsForHedgeInvestingActivities
21100000
CY2019Q3 us-gaap Payments For Hedge Investing Activities
PaymentsForHedgeInvestingActivities
25200000
CY2023Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2943000
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
3749000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
397057000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
396251000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2250000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
203750000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
201500000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
410500000
CY2023Q2 irwd Long Term Debt Maturities Interest Payments
LongTermDebtMaturitiesInterestPayments
10500000
CY2023Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2943000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
397057000
CY2015Q2 us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
21100000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35814000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6601000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42945000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12690000
CY2023Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
923000
CY2022Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
278000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
1220000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
-442000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
34891000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
6323000
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
41725000
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
13132000
CY2021Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
150000000.0
CY2023Q2 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
2800000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
10800000
CY2023Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
32900000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
123400000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
13100000
irwd Stock Repurchased And Retired During Period Average Price Per Share
StockRepurchasedAndRetiredDuringPeriodAveragePricePerShare
11.47
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33400000
us-gaap Unrecognized Tax Benefits Increases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
11000000.0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34400000
us-gaap Restructuring Charges
RestructuringCharges
12100000
us-gaap Payments For Restructuring
PaymentsForRestructuring
753000
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
11347000
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-23-014242-index-headers.html Edgar Link pending
0001558370-23-014242-index.html Edgar Link pending
0001558370-23-014242.txt Edgar Link pending
0001558370-23-014242-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
irwd-20230630.xsd Edgar Link pending
irwd-20230630x10q.htm Edgar Link pending
irwd-20230630xex31d1.htm Edgar Link pending
irwd-20230630xex31d2.htm Edgar Link pending
irwd-20230630xex32d1.htm Edgar Link pending
irwd-20230630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
irwd-20230630_def.xml Edgar Link unprocessable
irwd-20230630x10q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
irwd-20230630_cal.xml Edgar Link unprocessable
irwd-20230630_lab.xml Edgar Link unprocessable
irwd-20230630_pre.xml Edgar Link unprocessable